Evoke Neuroscience aims to develop Artificial Intelligence biomarker for Alzheimer’s disease diagnosis
NEW YORK, NY, USA, November 8, 2019 /EINPresswire.com/ — Evoke Neuroscience, a medical device company developing and commercializing technologies to aid in diagnosis of cognitive disorders, announced today initial enrollment of subjects participating in an IRB approved study to develop an Artificial Intelligence (AI) biomarker of mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Conducted […]
eVox Brain Map is operated by Evoke Neuroscience, a medical device company dedicated to developing and delivering the most important advances in brain science. Market leader in brain assessment and training, Evoke Neuroscience’s goal is to improve patient’s health, performance, and quality of life with cognitive clinical tools that are accessible, affordable, and easy to use. Formed in 2009 by research scientists, clinicians, medical doctors, and entrepreneurs, Evoke has been honored with Inc500 and TransTech200 awards for innovative work in the field.